The US Food and Drug Administration has issued a “Study May Proceed” letter approving the commencement of clinical study with IC14 in patients with the most severe form of heart attack.
Landmark Publication Points to IC14 Target in ALS-MND
ALS-MND is our leading clinical program in neurodegeneration; however Parkinson’s and Alzheimer’s disease are also coming into sharp focus with some extraordinary new data directly related to IC14.
FDA approves COVID-19 study
On June 3, the US FDA approved an Investigative New Drug (IND) application for IC14 together with remdesivir in 300 COVID-19 patients at risk of acute respiratory distress syndrome (ARDS).
New research links IC14 target to dementia
New research published in the world’s leading journal Neurology reports a link between higher levels of an inflammatory marker called sCD14 and a higher risk of developing dementia.
Australian Immunotherapy Selected for Revolutionary US Clinical Trial Platform Debut
An Australian immunotherapy drug will receive a huge boost when it is tested with four other new concepts across 54 clinical sites across the USA in a search for an effective treatment for ALS (a motor neuron disease).